CLOSE
For adults with open-angle glaucoma or ocular hypertension
For any additional questions on storage or handling, view full Prescribing Information.
Warnings and Precautions
Bacterial Keratitis: Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.
Contact Lenses: Contact lenses should be removed prior to using RHOPRESSA® and may be reinserted 15 minutes following its administration.
Adverse reactions
The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily were red eyes, in 53% of patients. Six percent of patients discontinued therapy due to red eyes. Other common (approximately 20%) adverse reactions were: small deposits on the outer surface of the eye, mild pain upon instillation, and broken blood vessels on the white of the eye. Instillation site redness, corneal staining, blurred vision, increased tearing, redness of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The small deposits on the outer surface of the eye seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most small deposits on the outer surface of the eye resolved upon discontinuation of treatment.
Please see full Rhopressa Prescribing Information at www.rhopressa.com.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATIONS AND USAGE
RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
Warnings and Precautions
Bacterial Keratitis: Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.
Contact Lenses: Contact lenses should be removed prior to using RHOPRESSA® and may be reinserted 15 minutes following its administration.
Adverse reactions
The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily were red eyes, in 53% of patients. Six percent of patients discontinued therapy due to red eyes. Other common (approximately 20%) adverse reactions were: small deposits on the outer surface of the eye, mild pain upon instillation, and broken blood vessels on the white of the eye. Instillation site redness, corneal staining, blurred vision, increased tearing, redness of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The small deposits on the outer surface of the eye seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most small deposits on the outer surface of the eye resolved upon discontinuation of treatment.
Please see full Rhopressa Prescribing Information at www.rhopressa.com.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATIONS AND USAGE
RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
